SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
Fuat Erdem 1 * , Mehmet Gündogdu 1, Ahmet Kiziltunç 2
More Detail
1 Ataturk University, Faculty of Medicine, Division of Hematology of the Department of Internal Medicine, Erzurum, Turkey
2 Ataturk University, Faculty of Medicine, Division of Hematology of the Department of Biochemistry, Erzurum, Turkey
* Corresponding Author

Abstract

Aim: Angiogenesis is an important factor in tumoral progression, metastasis and invasion. More recently, it has also been found to play a particular role in hematological malignancies. Methods: In this study, 45 patients harboring hematological malignancies (15 acute myeloid leukemia (AML), 10 acute lymphoblastic leukemia (ALL), 10 multiple myeloma (MM), 10 chronic myeloid leukemia (CML)) were compared with 20 healthy individuals matched according to age and sex, regarding serum vascular endothelial growth factor (VEGF, a marker for angiogenesis) levels. Results: The difference between serum VEGF levels of the study group (338.4 ± 587.6 pg/mL) and the control group (69.9 ± 24.4 pg/mL) was statistically significant (p<0.05). The highest serum VEGF level (1099.7±906.8 pg/mL) was found in CML subgroup. Conclusion: Serum VEGF levels of the patients with hematological malignancies were significantly higher compared to controls. Further studies are needed to determine the exact role of VEGF in the development and progression of the hematological malignancies and therapeutic implications of this finding.

License

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article Type: Original Article

https://doi.org/10.29333/ejgm/82390

EUR J GEN MED, 2006 - Volume 3 Issue 3, pp. 116-120

Publication date: 15 Jul 2006

Article Views: 791

Article Downloads: 394

Open Access References How to cite this article